BEXIMCO PHARMA.GDR REGS 1 (R2WA) - Total Liabilities
Based on the latest financial reports, BEXIMCO PHARMA.GDR REGS 1 (R2WA) has total liabilities worth €20.17 Billion EUR (≈ $23.58 Billion USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check R2WA cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
BEXIMCO PHARMA.GDR REGS 1 - Total Liabilities Trend (2021–2024)
This chart illustrates how BEXIMCO PHARMA.GDR REGS 1's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see R2WA total assets.
BEXIMCO PHARMA.GDR REGS 1 Competitors by Total Liabilities
The table below lists competitors of BEXIMCO PHARMA.GDR REGS 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
A Plus Asset Advisor Co Ltd
KO:244920
|
Korea | ₩266.75 Billion |
|
Kolon Corp
KO:002020
|
Korea | ₩4.72 Trillion |
|
Investcorp Europe Acquisition I Corp
NASDAQ:IVCB
|
USA | $10.09 Million |
|
Datawalk SA
WAR:DAT
|
Poland | zł105.76 Million |
|
LIFELINE SPAC I OYJ A EO1
F:0CD
|
Germany | €9.90 Million |
|
Beijing Chieftain Control Engineering Technology Co Ltd
SHE:300430
|
China | CN¥1.49 Billion |
|
DB INC
KO:012030
|
Korea | ₩464.00 Billion |
|
Peninsula Group Ltd
TA:PEN
|
Israel | ILA1.23 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down BEXIMCO PHARMA.GDR REGS 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See BEXIMCO PHARMA.GDR REGS 1 (R2WA) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BEXIMCO PHARMA.GDR REGS 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
The table below shows the annual total liabilities of BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €17.44 Billion ≈ $20.39 Billion |
-19.02% |
| 2023-06-30 | €21.54 Billion ≈ $25.18 Billion |
+0.12% |
| 2022-06-30 | €21.51 Billion ≈ $25.15 Billion |
+44.56% |
| 2021-06-30 | €14.88 Billion ≈ $17.40 Billion |
-- |
About BEXIMCO PHARMA.GDR REGS 1
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more